single nucleotide polymorphism reduces dabigatran acylglucuronide formation in humans.

Journal: Frontiers in pharmacology
Published Date: Jan 9, 2025

Abstract

BACKGROUND: Dabigatran etexilate (DABE), a prodrug of dabigatran (DAB), is a direct thrombin inhibitor used to prevent ischemic stroke and thromboembolism during atrial fibrillation. The effect of genetic polymorphisms on its metabolism, particularly , has not been extensively explored in humans. This study aimed to investigate the effects of , , and polymorphisms on the pharmacokinetics of DAB and its acylglucuronide metabolites in healthy subjects.

Authors

  • Jin-Woo Park
    Department of Clinical Pharmacology and Toxicology, Anam Hospital, Korea University College of Medicine, Seoul, Republic of Korea.
  • Jong-Min Kim
    Department of Clinical Pharmacology and Toxicology, Anam Hospital, Korea University College of Medicine, Seoul, Republic of Korea.
  • Young Yoon Bang
    Department of Clinical Pharmacology and Toxicology, Anam Hospital, Korea University College of Medicine, Seoul, Republic of Korea.
  • Kyoung-Ah Kim
    Department of Clinical Pharmacology and Toxicology, Anam Hospital, Korea University College of Medicine, Seoul, Republic of Korea.
  • Sungwook Yu
    Department of Neurology, Anam Hospital, Korea University College of Medicine, Seoul, Republic of Korea.
  • Ji-Young Park
    Department of Clinical Pharmacology and Toxicology, Anam Hospital, Korea University College of Medicine, Seoul, Republic of Korea.

Keywords

No keywords available for this article.

External Resources

Popular Topics
Recent Journals